JP2023531919A5 - - Google Patents
Info
- Publication number
- JP2023531919A5 JP2023531919A5 JP2022578616A JP2022578616A JP2023531919A5 JP 2023531919 A5 JP2023531919 A5 JP 2023531919A5 JP 2022578616 A JP2022578616 A JP 2022578616A JP 2022578616 A JP2022578616 A JP 2022578616A JP 2023531919 A5 JP2023531919 A5 JP 2023531919A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- weeks
- patient
- form according
- administered daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043681P | 2020-06-24 | 2020-06-24 | |
| US63/043,681 | 2020-06-24 | ||
| PCT/US2021/038789 WO2021262914A1 (en) | 2020-06-24 | 2021-06-24 | Compositions and methods for treating obsessive-compulsive disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531919A JP2023531919A (ja) | 2023-07-26 |
| JP2023531919A5 true JP2023531919A5 (https=) | 2024-06-28 |
| JP7805969B2 JP7805969B2 (ja) | 2026-01-26 |
Family
ID=79281806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578616A Active JP7805969B2 (ja) | 2020-06-24 | 2021-06-24 | 強迫性障害を治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230181541A1 (https=) |
| EP (1) | EP4171554A4 (https=) |
| JP (1) | JP7805969B2 (https=) |
| KR (1) | KR20230027189A (https=) |
| CN (1) | CN115968312A (https=) |
| AU (1) | AU2021297249A1 (https=) |
| BR (1) | BR112022025901A2 (https=) |
| CA (1) | CA3187323A1 (https=) |
| IL (1) | IL299301A (https=) |
| MX (1) | MX2022016174A (https=) |
| PH (1) | PH12022553441A1 (https=) |
| WO (1) | WO2021262914A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP2400349A1 (hu) * | 2024-07-05 | 2026-01-28 | Egis Gyógyszergyár Zrt. | Troriluzole-hidroklorid-sók |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564187T3 (es) * | 2005-04-05 | 2016-03-18 | Yale University | Agentes de modulación de glutamato en el tratamiento de trastornos mentales |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| JP2018521007A (ja) * | 2015-05-22 | 2018-08-02 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの治療的使用 |
| TW202000205A (zh) * | 2018-02-21 | 2020-01-01 | 美商Ａｉ治療公司 | 使用阿吡莫德與麩胺酸性劑的組合治療 |
| MX2020012377A (es) * | 2018-05-27 | 2021-04-12 | Biohaven Therapeutics Ltd | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. |
| MX2021000515A (es) * | 2018-07-22 | 2021-06-08 | Biohaven Therapeutics Ltd | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. |
| US20210315865A1 (en) * | 2018-08-16 | 2021-10-14 | Biohaven Therapeutics Ltd. | Use of riluzole oral disintigrating tablets for treating diseases |
-
2021
- 2021-06-24 JP JP2022578616A patent/JP7805969B2/ja active Active
- 2021-06-24 PH PH1/2022/553441A patent/PH12022553441A1/en unknown
- 2021-06-24 MX MX2022016174A patent/MX2022016174A/es unknown
- 2021-06-24 BR BR112022025901A patent/BR112022025901A2/pt unknown
- 2021-06-24 US US17/923,587 patent/US20230181541A1/en active Pending
- 2021-06-24 KR KR1020237001813A patent/KR20230027189A/ko active Pending
- 2021-06-24 AU AU2021297249A patent/AU2021297249A1/en active Pending
- 2021-06-24 CA CA3187323A patent/CA3187323A1/en active Pending
- 2021-06-24 EP EP21829058.3A patent/EP4171554A4/en active Pending
- 2021-06-24 CN CN202180044180.1A patent/CN115968312A/zh active Pending
- 2021-06-24 IL IL299301A patent/IL299301A/en unknown
- 2021-06-24 WO PCT/US2021/038789 patent/WO2021262914A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2435041B1 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| CA2529742A1 (en) | Composition of a vegf antagonist and an anti-proliferative agent | |
| JP2017529382A5 (https=) | ||
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| JP2021530543A5 (https=) | ||
| Younis et al. | CGRP receptor antagonists (gepants) | |
| JP2023531919A5 (https=) | ||
| JP2005525409A5 (https=) | ||
| JP2025517509A5 (https=) | ||
| WO2004054586A1 (en) | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors | |
| KR20050075012A (ko) | 항암제에 의해 유발된 말초신경증의 예방 및/또는 치료를위한 아세틸-ｌ-카르니틴 | |
| CN100355421C (zh) | 二十二碳六烯酸作为活性物质制备用于治疗脂肪代谢障碍的药物的用途 | |
| WO2018132791A1 (en) | Treatment of neurodegenerative conditions by disruption of rhes | |
| US20240207199A1 (en) | Fluorocarbon compositions and methods for enhancing immunotherapy | |
| JP2024518426A5 (https=) | ||
| US20210386736A1 (en) | Combination therapy for treating cancer | |
| HUP0202120A2 (hu) | Daganatellenes kombináció | |
| Sims-McCallum | Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| Kim et al. | Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer | |
| JP6243850B2 (ja) | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 | |
| Keady et al. | Caspofungin in the treatment of invasive fungal infections | |
| HK40040830A (en) | Combination therapy for treating cancer | |
| US20240122916A1 (en) | Effect of YEL002 on Conditions and Diseases |